We are analyzing https://link.springer.com/article/10.1186/1475-2891-13-17.

Title:
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review | Nutrition Journal
Description:
Peroxisome proliferator-activated receptors are expressed in many tissues, including adipocytes, hepatocytes, muscles and endothelial cells; however, the affinity depends on the isoform of PPAR, and different distribution and expression profiles, which ultimately lead to different clinical outcomes. Because they play an important role in lipid and glucose homeostasis, they are called lipid and insulin sensors. Their actions are limited to specific tissue types and thus, reveal a characteristic influence on target cells. PPARα mainly influences fatty acid metabolism and its activation lowers lipid levels, while PPARγ is mostly involved in the regulation of the adipogenesis, energy balance, and lipid biosynthesis. PPARβ/δ participates in fatty acid oxidation, mostly in skeletal and cardiac muscles, but it also regulates blood glucose and cholesterol levels. Many natural and synthetic ligands influence the expression of these receptors. Synthetic ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists). New generation drugs - PPARα/γ dual agonists - reveal hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action while the overexpression of PPARβ/δ prevents the development of obesity and reduces lipid accumulation in cardiac cells, even during a high-fat diet. Precise data on the expression and function of natural PPAR agonists on glucose and lipid metabolism are still missing, mostly because the same ligand influences several receptors and a number of reports have provided conflicting results. To date, we know that PPARs have the capability to accommodate and bind a variety of natural and synthetic lipophilic acids, such as essential fatty acids, eicosanoids, phytanic acid and palmitoylethanolamide. A current understanding of the effects of PPARs, their molecular mechanisms and the role of these receptors in nutrition and therapeutic treatment are delineated in this paper.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

pubmed, article, google, scholar, cas, pparγ, fatty, diabetes, lipid, acids, receptor, ppar, pparα, receptors, agonists, peroxisome, acid, ligands, glucose, type, cancer, activation, cells, ppars, expression, treatment, effects, proliferatoractivated, metabolism, insulin, figure, pparβδ, human, role, tissue, patients, oxidation, natural, function, gene, central, study, mellitus, cardiovascular, metabolic, adipose, clinical, development, liver, res,

Topics {✒️}

peroxisome-proliferator activated receptors peroxisome proliferator-activated receptors peroxisome-proliferator-activated receptors peroxisome proliferator-activated receptor fatty acid-binding protein pparβ/δ-deficient mice challenged nuclear hormone receptors phospholipase a2-dependent manner mediated flow-dependent dilations article grygiel-górniak bogna grygiel-górniak pparα/γ dual agonists ligand-activated transcription factors activated nf-κb attention-deficit/hyperactivity disorder [25] dose-dependently improves glucose steroid hormone receptors ligand-independent activation domain full ppar-γ agonists article download pdf microsomal omega-oxidation system open access license fatty acid-β-oxidation long-term fenofibrate therapy choline deficiency-induced steatohepatitis ligand binding domain called insulin-sensitizing medications a-ii gene expression decreased pparβ/δ expression full size image aleglitazar decreased hba1c streptozotocin-induced diabetic rats troglitazone revealed tumor-promoting including drug related chain lengths longer ppar delta functions long-term fenofibrate treatment ppar-regulated gene expression related subjects pparβ/δ activation led γ receptor subtypes inhibit receptor function pparβ/δ pparβ/δ authors’ original file long-term studies individual ppar receptors increasing apolipoprotein a lower blood pressure pparα receptors connect fatty acids increases

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
         description:Peroxisome proliferator-activated receptors are expressed in many tissues, including adipocytes, hepatocytes, muscles and endothelial cells; however, the affinity depends on the isoform of PPAR, and different distribution and expression profiles, which ultimately lead to different clinical outcomes. Because they play an important role in lipid and glucose homeostasis, they are called lipid and insulin sensors. Their actions are limited to specific tissue types and thus, reveal a characteristic influence on target cells. PPARα mainly influences fatty acid metabolism and its activation lowers lipid levels, while PPARγ is mostly involved in the regulation of the adipogenesis, energy balance, and lipid biosynthesis. PPARβ/δ participates in fatty acid oxidation, mostly in skeletal and cardiac muscles, but it also regulates blood glucose and cholesterol levels. Many natural and synthetic ligands influence the expression of these receptors. Synthetic ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists). New generation drugs - PPARα/γ dual agonists - reveal hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action while the overexpression of PPARβ/δ prevents the development of obesity and reduces lipid accumulation in cardiac cells, even during a high-fat diet. Precise data on the expression and function of natural PPAR agonists on glucose and lipid metabolism are still missing, mostly because the same ligand influences several receptors and a number of reports have provided conflicting results. To date, we know that PPARs have the capability to accommodate and bind a variety of natural and synthetic lipophilic acids, such as essential fatty acids, eicosanoids, phytanic acid and palmitoylethanolamide. A current understanding of the effects of PPARs, their molecular mechanisms and the role of these receptors in nutrition and therapeutic treatment are delineated in this paper.
         datePublished:2014-02-14T00:00:00Z
         dateModified:2014-02-14T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/1475-2891-13-17
         keywords:
            Rosiglitazone
            Pioglitazone
            Fatty Acid Oxidation
            Phytanic Acid
            Bezafibrate
            Clinical Nutrition
            Health Promotion and Disease Prevention
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig6_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig7_HTML.jpg
         isPartOf:
            name:Nutrition Journal
            issn:
               1475-2891
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Bogna Grygiel-Górniak
               affiliation:
                     name:University of Medical Sciences
                     address:
                        name:Department of Bromatology and Human Nutrition, University of Medical Sciences, Poznan, Poland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
      description:Peroxisome proliferator-activated receptors are expressed in many tissues, including adipocytes, hepatocytes, muscles and endothelial cells; however, the affinity depends on the isoform of PPAR, and different distribution and expression profiles, which ultimately lead to different clinical outcomes. Because they play an important role in lipid and glucose homeostasis, they are called lipid and insulin sensors. Their actions are limited to specific tissue types and thus, reveal a characteristic influence on target cells. PPARα mainly influences fatty acid metabolism and its activation lowers lipid levels, while PPARγ is mostly involved in the regulation of the adipogenesis, energy balance, and lipid biosynthesis. PPARβ/δ participates in fatty acid oxidation, mostly in skeletal and cardiac muscles, but it also regulates blood glucose and cholesterol levels. Many natural and synthetic ligands influence the expression of these receptors. Synthetic ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists). New generation drugs - PPARα/γ dual agonists - reveal hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action while the overexpression of PPARβ/δ prevents the development of obesity and reduces lipid accumulation in cardiac cells, even during a high-fat diet. Precise data on the expression and function of natural PPAR agonists on glucose and lipid metabolism are still missing, mostly because the same ligand influences several receptors and a number of reports have provided conflicting results. To date, we know that PPARs have the capability to accommodate and bind a variety of natural and synthetic lipophilic acids, such as essential fatty acids, eicosanoids, phytanic acid and palmitoylethanolamide. A current understanding of the effects of PPARs, their molecular mechanisms and the role of these receptors in nutrition and therapeutic treatment are delineated in this paper.
      datePublished:2014-02-14T00:00:00Z
      dateModified:2014-02-14T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/1475-2891-13-17
      keywords:
         Rosiglitazone
         Pioglitazone
         Fatty Acid Oxidation
         Phytanic Acid
         Bezafibrate
         Clinical Nutrition
         Health Promotion and Disease Prevention
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig6_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2891-13-17/MediaObjects/12937_2013_Article_757_Fig7_HTML.jpg
      isPartOf:
         name:Nutrition Journal
         issn:
            1475-2891
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Bogna Grygiel-Górniak
            affiliation:
                  name:University of Medical Sciences
                  address:
                     name:Department of Bromatology and Human Nutrition, University of Medical Sciences, Poznan, Poland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Nutrition Journal
      issn:
         1475-2891
      volumeNumber:13
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Medical Sciences
      address:
         name:Department of Bromatology and Human Nutrition, University of Medical Sciences, Poznan, Poland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Bogna Grygiel-Górniak
      affiliation:
            name:University of Medical Sciences
            address:
               name:Department of Bromatology and Human Nutrition, University of Medical Sciences, Poznan, Poland
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Bromatology and Human Nutrition, University of Medical Sciences, Poznan, Poland

External Links {🔗}(274)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.77s.

LINK . SPRINGER . COM {}